This year, without the restrictions of COVID-19, the communication activity between suppliers and customers are frequent than the last several years. And the site audit and inspection are hot.
In the first half of the year, our facility were inspected by customers for more than ten times. Thereinto, three times for international audit. The main products involve L-malic aicd, Dextran 40, Dextran 70 and Dextran 10. All inspection were approved, and the results were acceptable by customers.
We, Xi’an Wanlong Pharmaceutical Co., Ltd are ready and willing to be inspected by the customers or the regulatory agency.
We produce APIs, tablets, capsule, granules and injection, total 46 drug approval numbers and other intermediates. There are 4 API workshops, one solid preparation workshop, one large volume injection workshop one small volume injection workshop. Annual production capacity of 100 tons of APIs, solid dosage form annual output of 3 billion, injection annual output 1.3 billion bags. The drug products are widely used in the most provinces of China, and API exports to all over the world.We have the rights of self-operated import and export and welcome the clients around the world to cooperate with us.